Advances in regenerative medicine, particularly stem cells and 3D-bioprinted organs, could soon make heart transplantation an obsolete medical procedure.
Category: biotech/medical – Page 2,719
Researchers Created a Platform That Prints With Living Matter
3D printing has come a long way. In a new study, scientists explore the potential of using bacteria-laced ink to print living materials.
From pizza to urine-based space plastic and even blood vessels, it seems there’s no limit to what can be 3D printed. A new 3D printing platform, created by ETH researchers led by Professor André Studart, head of the Laboratory for Complex Materials, is advancing the process by working with living materials. The specially designed material is actually an ink infused with bacteria. The machine is then able to print living biochemical designs for a wide variety of purposes, which vary depending on the bacteria used. Their research has been published in Science Advances.
Scientists Just Took a Giant Leap Forward in the Quest to Create Artificial Life
A new study reveals that semi-synthetic organisms — in this case, E.coli bacteria containing two artificial DNA bases — can produce proteins.
A Modified CRISPR Could Treat Common Diseases Without Editing DNA
It worked. Working with mice, they were able to reverse the disease symptoms of kidney disease, type 1 diabetes, and a form of muscular dystrophy. In the mouse with kidney disease, for example, they turned on two genes associated with kidney function and saw the kidney function improved.
The unassumingly named CRISPR/Cas9 is a technology that stands to remake the world as we know it. By allowing scientists to more easily than ever cut and paste all those As, Cs, Ts, and Gs that encode all the world’s living things, for one thing, it could one day cure many devastating diseases.
All that power, though, comes with one pretty sizable caveat: Sometimes CRISPR doesn’t work quite like we expect it to. While the scientific establishment is still embroiled in a debate over just how serious the problem is, CRISPR sometimes causes off-target effects. And for scientists doing gene editing on human patients, those mutations could wind up inadvertently causing problems like tumors or genetic disease. Yikes.
Siddhartha Mukherjee meets Henry Marsh: ‘When do you stop treating a patient? At 100?’
Mukherjee is now 47 and lives in New York; Marsh, 67, lives in Oxford. To different extents both of these doctors still practise in their respective fields – Mukherjee at Columbia University’s cancer centre, Marsh as a visiting doctor at various hospitals around the world, including in Kathmandu in Nepal. Both men have continued to write: Marsh a second volume of autobiography, called Admissions, published this year, and Mukherjee a study of genetics called The Gene: An Intimate History, published last year. When they sat down to talk to each other over Skype one Saturday afternoon in November, they began with a subject on which their two lifelong disciplines overlap: the treatment of brain cancer.
The cancer specialist and the neurosurgeon talk about treating cancer, writing and facing death in their own families by Tom Lamont.
SENS: Progress in the Fight Against Age-related Diseases
Given there is to be a Reddit AMA on December 7th with Dr. Aubrey de Grey in the futurology subreddit, we thought it was a great time to have a look at the progress the SENS Research Foundation has made in tackling the aging processes. What follows is a brief summary of some of the highlights of their research efforts as well as the details of the AMA where you can ask Aubrey anything you like about his work.
Given that there is to be a Reddit AMA on December 7th with Dr. Aubrey de Grey in the Futurology subreddit, we think it’s a great time to have a look at the progress that the SENS Research Foundation has made in tackling the aging processes. What follows is a brief summary of some of the highlights of their research efforts as well as the details of the AMA, in which you can ask Aubrey anything you like about his work.
Today, there are many drugs and therapies that we take for granted. However, we should not forget that what is common and easily accessible today didn’t just magically appear out of thin air; rather, at some point, it used to be an unclear subject of study on which “more research was needed”, and even earlier, it was just a conjecture in some researcher’s head.
Hopefully, one day not too far into the future, rejuvenation biotechnologies will be as normal and widespread as aspirin is today, but right now, we’re in the R&D phase, so we should be patient and remind ourselves that the fact that we can’t rejuvenate people today doesn’t mean that nothing is being done or has been achieved to that end. On the contrary, we are witnessing exciting progress in basic research—the fundamental building blocks without which rejuvenation, or any new technology at all, would stay a conjecture.
We are happy to announce Dr. Jean Hébert as a speaker for the 2018 Undoing Aging Conference
Dr. Hébert will be in Berlin to provide an update on his fascinating work. The use of stem cells to repair the brain is relatively straightforward for Parkinson’s disease, in which cell depletion is localized to one small region, but in Alzheimer’s disease and other conditions, the cell loss is widely distributed, whereas cells can only be injected into one spot. The solution that Dr. Hébert explores is to make those cells migrate before dividing and differentiating.
https://www.undoing-aging.org/dr-jean-hebert-to-speak-at-undoing-aging-2018